Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (previously presented): A compound of formula (I), or a solvate or pharmaceutically acceptable salt thereof:



(I)

wherein, independently at each occurrence,

n is selected from 1, 2, 3 and 4;

X is selected from a direct bond, and -C(R_6,R_{14})-Y-,

Y is selected from a direct bond, O, S, and C_1-C_4alkylene;

R_{13} is selected from hydrogen, C_1-C_6alkyl, C_3-C_8cycloalkyl, aryl, and benzyl;

R_1 and R_2 are independently selected from hydrogen, C_1-C_8alkyl, C_3-C_8alkoxyalkyl, C_1-C_8hydroxyalkyl, and C_7-C_{12}aralkyl; or

R_1 and R_2, are taken together with the nitrogen atom to which they are directly attached in formula (I), to form a ring denoted by formula (II):



(II)

wherein the ring of formula (II) is formed from the nitrogen as shown as well as three to nine additional ring atoms independently selected from carbon, nitrogen, oxygen, and sulfur; where any two adjacent ring atoms may be joined together by single or double bonds, and where any one or more of the additional carbon ring atoms may be substituted with one or two substituents selected from hydrogen, hydroxy, C_1-C_3hydroxyalkyl, oxo, C_2-C_4acyl, C_1-C_3alkyl, C_2-C_4alkylcarboxy, C_1-C_3alkoxy, C_1-C_{20}alkanoyloxy, or may be substituted to form a spiro five- or six-membered heterocyclic ring containing one or two heteroatoms selected from oxygen and sulfur; and any two adjacent additional carbon ring atoms may be fused to a C_3-C_8carbocyclic ring, and any one or more of the additional nitrogen ring atoms may be substituted with substituents selected from hydrogen, C_1-C_6alkyl, C_2-C_4acyl, C_2-C_4hydroxyalkyl and C_3-C_8alkoxyalkyl; or

R_1 and R_2, are taken together with the nitrogen atom to which they are directly attached in formula (I), to form a bicyclic ring system selected from 3-azabicyclo[3.2.2]nonan-3-yl, 2-azabicyclo[2.2.2]octan-2-yl, 3-azabicyclo[3.1.0]hexan-3-yl, and 3-azabicyclo[3.2.0]heptan-3-yl;

R_3 and R_4 are independently attached to the cycloalkyl ring shown in formula (I) at other than the 1 and 2 positions and are independently selected from hydrogen, hydroxy, C_1-C_6alkyl, and C_1-C_6alkoxy, and, when both R_3 and R_4 are attached to the same cycloalkane ring atom, may together form a spiro five- or six-membered heterocyclic ring containing one or two heteroatoms selected from oxygen and sulfur;

R_5, R_6 and R_{14} are independently selected from hydrogen, C_1-C_6alkyl, aryl and benzyl, or R_6 and R_{14}, when taken together with the carbon to which they are attached, may form a spiro C_3-C_5cycloalkyl;

A is selected from C_5-C_{12}alkyl, a C_3-C_{13}carbocyclic ring, and ring systems selected from formulae (III), (IV), (V), (VI), (VII) and (VIII):



(III)

where R_7, R_8 and R_9 are independently selected from bromine, chlorine, fluorine, carboxy, hydrogen, hydroxy, hydroxymethyl, methanesulfonamido, nitro, sulfamyl, trifluoromethyl, C_2-C_7alkanoyloxy, C_1-C_6alkyl, C_1-C_6alkoxy, C_2-C_7alkoxycarbonyl, C_1-C_6thioalkyl, aryl and $N(R_{15},R_{16})$ where R_{15} and R_{16} are independently selected from hydrogen, acetyl, methanesulfonyl, and C_1-C_6alkyl;



and



(IV) (V)

where R_{10} and R_{11} are independently selected from bromine, chlorine, fluorine, carboxy, hydrogen, hydroxy, hydroxymethyl, methanesulfonamido, nitro, sulfamyl, trifluoromethyl, C_2-C_7alkanoyloxy, C_1-C_6alkyl, C_1-C_6alkoxy, C_2-C_7alkoxycarbonyl, C_1-C_6thioalkyl, and $N(R_{15},R_{16})$ where R_{15} and R_{16} are independently selected from hydrogen, acetyl, methanesulfonyl, and C_1-C_6alkyl;



(VI)

where R_{12} is selected from bromine, chlorine, fluorine, carboxy, hydrogen, hydroxy, hydroxymethyl, methanesulfonamido, nitro, sulfamyl, trifluoromethyl, C_2-C_7alkanoyloxy, C_1-C_6alkyl, C_1-C_6alkoxy, C_2-C_7alkoxycarbonyl, C_1-C_6thioalkyl, and $N(R_{15},R_{16})$ where R_{15} and R_{16} are independently selected from hydrogen, acetyl, methanesulfonyl, and C_1-C_6alkyl; and Z is selected from CH, CH_2, O, N and S, where Z may be directly bonded to the carbon atom in formula (I) that is shown directly bonded to "A" when Z is CH or N, or Z may be directly bonded to R_{17} when Z is N, and R_{17} is selected from hydrogen, C_1-C_6alkyl, C_3-C_8cycloalkyl, aryl and benzyl;



(VII)



(VIII)

including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof;

with the proviso that the compound of formula (I) is not (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide or a mixture of (1R,2S) -N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide and (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide.

Claim 2 (previously presented): A mixture of compounds selected from the group consisting of: a mixture of (1R,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide monohydrochloride and (1S,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide monohydrochloride; a mixture of (1R,2R) -N-[2-(4-morpholinyl)cyclohexyl]-3,4-dichlorocinnamide monohydrochloride and (1S,2S)-N-[2-(4-morpholinyl)cyclohexyl]-3,4-dichlorocinnamide monohydrochloride; a mixture of (1R,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclopentyl]-3,4-dichlorocinnamide monohydrochloride and (1S,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclopentyl]-3,4-dichlorocinnamide monohydrochloride, and pharmaceutically acceptable salts and solvates of any of the foregoing.

Claim 3 (previously presented): A composition comprising a pharmaceutically acceptable carrier, excipient or diluent and a compound according to claim 1, claim 2, or a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 4 (cancelled)

Claim 5 (previously presented): A method for treating arrhythmia in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or claim 2 or a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 6 (previously presented): A method for modulating ion channel activity in a warm-blooded animal, the method comprising administering to a warm-blooded animal in need thereof an amount of a compound effective to modulate ion channel activity in the warm-blooded animal, wherein the compound is a compound according to claim 1 or claim 2 or a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 7 (previously presented): A method for modulating ion channel activity *in vitro* comprising contacting an ion channel *in vitro* with an amount of a compound effective to modulate ion channel activity, wherein the compound is a compound according to claim 1 or claim 2 or is a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claims 8 – 37 (cancelled)

Claim 38 (previously presented): A pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent, or excipient and an amount of a compound effective to treat a cardiovascular disease in a warm-blooded animal in need thereof, wherein the compound is a

compound according to claim 1 or claim 2 or is a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 39 (previously presented): A method for treating a cardiovascular disease in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or claim 2 or a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 40 (previously presented): A pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent, or excipient and an amount of a compound effective to treat cerebral or myocardial ischemias in a warm-blooded animal, wherein the compound is a compound according to claim 1 or claim 2 or is a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 41 (previously presented): A method for treating cerebral or myocardial ischemias in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or claim 2 or a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 42 (previously presented): A pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent, or excipient and an amount of a compound effective to

treat hypertension in a warm-blooded animal, wherein the compound is a compound according to claim 1 or claim 2 or is a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 43 (previously presented): A method for treating hypertension in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or claim 2 or a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 44 (previously presented): A pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent, or excipient and an amount of a compound effective to treat long-QT syndrome in a warm-blooded animal, wherein the compound is a compound according to claim 1 or claim 2 or is a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 45 (previously presented): A method for treating long-QT syndrome in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or claim 2 or a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 46 (previously presented): A pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent, or excipient and an amount of a compound effective to

treat stroke in a warm-blooded animal, wherein the compound is a compound according to claim 1 or claim 2 or is a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 47 (previously presented): A method for treating stroke in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or claim 2 or a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claims 48-71 (cancelled).

Claim 72 (previously presented): A pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent, or excipient and an amount of a compound effective to produce local analgesia or anesthesia in a warm-blooded animal, wherein the compound is a compound according to claim 1 or claim 2 or is a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 73 (previously presented): A method for producing local analgesia or anesthesia in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or claim 2 or a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 74 (previously presented): A pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent, or excipient and an amount of a compound effective to treat heart failure in a warm-blooded animal, wherein the compound is a compound according to claim 1 or claim 2 or is a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 75 (previously presented): A method for treating heart failure in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or claim 2 or a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claims 76 - 83 (cancelled).

Claim 84 (previously presented): A pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent, or excipient and an amount of a compound effective to enhance libido in a warm-blooded animal, wherein the compound is a compound according to claim 1 or claim 2 or is a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 85 (previously presented): A method for enhancing libido in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof an enhancing amount of a compound according to claim 1 or claim 2 or a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 86 (previously presented): A method for providing therapy for atrial arrhythmia in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or claim 2 or a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 87 (previously presented): A method for providing therapy for ventricular arrhythmia in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or claim 2 or a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 88 (previously presented): A method for treating atrial fibrillation in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or claim 2 or a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 89 (previously presented): A method of treating ventricular fibrillation in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or claim 2 or a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 90 (previously presented): A pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent, or excipient and an amount of a compound effective to block an ion channel in a warm-blooded animal, wherein the compound is a compound according to claim 1 or claim 2 or is a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 91 (previously presented): A pharmaceutical composition according to claim 90, wherein the ion channel is a cardiac sodium channel.

Claim 92 (previously presented): A pharmaceutical composition according to claim 90, wherein the ion channel is a cardiac potassium channel.

Claim 93 (previously presented): A method for blocking an ion channel in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof an amount of a compound effective to block an ion channel in the warm blooded animal, wherein the compound is a compound according to claim 1 or claim 2 or is a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 94 (previously presented): A method according to claim 93, wherein the ion channel is a cardiac sodium channel.

Claim 95 (previously presented): A method according to claim 93, wherein the ion channel is a cardiac potassium channel.

Claim 96 (previously presented): A method for preventing arrhythmia in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or claim 2 or a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 97 (previously presented): A method for preventing cerebral or myocardial ischemias in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or claim 2 or a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 98 (previously presented): A method for preventing heart failure in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or claim 2 or a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 99 (previously presented): A method for treating atrial arrhythmia in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or claim 2 or a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 100 (previously presented): A method for preventing atrial arrhythmia in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or claim 2 or a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 101 (previously presented): A method for treating ventricular arrhythmia in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or claim 2 or a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 102 (previously presented): A method for preventing ventricular arrhythmia in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or claim 2 or a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 103 (previously presented): A method for preventing atrial fibrillation in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or claim 2 or a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-

dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 104 (previously presented): A method of preventing ventricular fibrillation in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or claim 2 or a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 105 (previously presented): A pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent, or excipient and an amount of a compound effective to treat a condition selected from the group consisting of central nervous system diseases, convulsions, epileptic spasms, depression, anxiety, schizophrenia, Parkinson's disease, respiratory disorders, cystic fibrosis, asthma, cough, inflammation, arthritis, allergies, gastrointestinal disorders, incontinence, irritable bowel syndrome, migraine, ophthalmic diseases, diabetes mellitus, myopathies, Becker's myotonia, myasthenia gravis, paramyotonia congentia, malignant hyperthermia, hyperkalemic periodic paralysis Thomsen's myotonia, autoimmune disorders, graft rejection in organ transplantation or bone morrow transplantation, hypotension, Alzheimer's disease, dementia, or alopecia;

wherein the compound is a compound according to claim 1 or claim 2 or is a compound selected from the group consisting of (1R,2S)-*N*-methyl-*N*-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-*N*-methyl-*N*-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, or mixtures thereof.

Claim 106 (previously presented): A method for treating a condition in a warm-blooded animal, wherein:

the condition is selected from the group consisting of central nervous system diseases, convulsions, epileptic spasms, depression, anxiety, schizophrenia, Parkinson's disease, respiratory disorders, cystic fibrosis, asthma, cough, inflammation, arthritis, allergies, gastrointestinal disorders, incontinence, irritable bowel syndrome, migraine, ophthalmic diseases, diabetes mellitus, myopathies, Becker's myotonia, myasthenia gravis, paramyotonia congentia, malignant hyperthermia, hyperkalemic periodic paralysis Thomsen's myotonia, autoimmune disorders, graft rejection in organ transplantation or bone morrow transplantation, hypotension, Alzheimer's disease, dementia, or alopecia; and

the method comprises administering to a warm-blooded animal in need thereof an amount of a compound according to claim 1 or claim 2 or a compound selected from the group consisting of (1R,2S)-*N*-methyl-*N*-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-*N*-methyl-*N*-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, or mixtures thereof, effective to treat the condition.

Claim 107 (previously presented): A method for preventing a condition in a warm-blooded animal, wherein:

the condition is selected from the group consisting of central nervous system diseases, convulsions, epileptic spasms, depression, anxiety, schizophrenia, Parkinson's disease, respiratory disorders, cystic fibrosis, asthma, cough, inflammation, arthritis, allergies, gastrointestinal disorders, incontinence, irritable bowel syndrome, migraine, ophthalmic diseases, diabetes mellitus, myopathies, Becker's myotonia, myasthenia gravis, paramyotonia congentia, malignant hyperthermia, hyperkalemic periodic paralysis Thomsen's myotonia, autoimmune disorders, graft rejection in organ transplantation or bone morrow transplantation, hypotension, Alzheimer's disease, dementia, or alopecia; and

the method comprises administering to a warm-blooded animal in need thereof an amount of a compound according to claim 1 or claim 2 or a compound selected from the group consisting of (1R,2S)-*N*-methyl-*N*-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-*N*-methyl-*N*-

[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, or mixtures thereof, effective to prevent the condition.

Claim 108 (previously presented): A pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent, or excipient and an amount of a compound effective to provide therapy for arrhythmia in a warm-blooded animal, wherein the compound is a compound according to claim 1 or claim 2 or is a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 109 (previously presented): A method for providing therapy for arrhythmia in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or claim 2 or a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 110 (previously presented): A method for preventing hypertension in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or claim 2 or a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 111 (previously presented): A method for preventing long-QT syndrome in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or claim 2 or a compound

selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 112 (previously presented): A method for preventing stroke in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or claim 2 or a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 113 (previously presented): A method for preventing a cardiovascular disease in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or claim 2 or a compound selected from the group consisting of (1R,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, (1S,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide, and mixtures thereof.

Claim 114 (previously presented): A compound selected from the group consisting of: (1R,2R) -N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide monohydrochloride, (1S,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-3,4-dichlorocinnamide monohydrochloride, (1R,2R)-N-[2-(4-morpholinyl)cyclohexyl]-3,4-dichlorocinnamide monohydrochloride, (1S,2S)-N-[2-(4-morpholinyl)cyclohexyl]-3,4-dichlorocinnamide monohydrochloride, (1R,2R)-N-methyl-N-[2-(1-pyrrolidinyl)cyclopentyl]-3,4-dichlorocinnamide monohydrochloride, and (1S,2S)-N-methyl-N-[2-(1-pyrrolidinyl)cyclopentyl]-3,4-dichlorocinnamide monohydrochloride, and pharmaceutically acceptable salts and solvates of any of the foregoing.